Similarly, Vasohibin 2 (VASH2) protein suppresses pancreatic CSCs through decreasing SMO and Gli1/2 (Yang et al., 2020), while also functioning as a tumor promoter, stimulating resistance to doxorubicin (DOX) (Mirzaei et al., 2021) upregulating pancreatic CSCs via the Hh and Notch pathways (Liang et al., 2021a). The gene discussed is SMO; the disease is neoplasm.